Advertisement
News
Advertisement

Dako and Amgen Expand Collaboration with Plan to Develop New Diagnostic Test

Tue, 02/11/2014 - 12:12pm
Dako

Dako, an Agilent Technologies company and worldwide provider of cancer diagnostics, today announced a new project with Amgen to develop a molecular diagnostic test using Dako's IQFISH hybridization buffer.

"We are pleased to continue our work with Amgen, particularly within the molecular arena," said Jacob Thaysen, vice president and general manager for Agilent's Diagnostics and Genomics business. "We are excited to expand this collaboration into even more projects."

The cutting-edge IQFISH hybridization buffer, introduced by Dako in 2012, reduces diagnostic test turnaround time from 17 hours to just 3.5 hours. It enables pathology labs-for the first time-to run DNA-based hybridization assays quickly, with distinct and higher fluorescent signal intensity compared to traditional FISH assays. This ability represents a major advance for pathologists, oncologists and ultimately patients.

Companion diagnostics are becoming increasingly important in treating disease. They provide a way to both improve patient care and reduce health-care costs by matching specific therapies to the individuals most likely to benefit from them, since all patients do not respond in the same way.

Dako partners with top-tier pharma companies for the development of companion diagnostics. Its track record in companion diagnostics continues to attract new partners, as well as add new projects with current partners.

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading